|
|
|
|
| Join editor Jeff Buguliskis on June 4, 2026, at 11 a.m. ET for Outsourced Pharma Live: Beyond Data Packages: Derisking Tech Transfer To CDMOs. Industry experts will explore how sponsors can better prepare for successful tech transfers by addressing common challenges including incomplete data packages, equipment differences, method variability, global standards, and CMC alignment. Learn strategies using smarter documentation, DOE, and in silico modeling to improve right-first-time transfer success. Register now |
|
|
|
| 6 Strategic Pillars For Selecting A Drug Packaging Partner | Article | By Scott Mills and Armando Pedoto, Sr., Adare Pharma Solutions | Early engagement with an expert packaging partner supports safe, cost-effective drug development and logistical success from precommercial stages through full market launch. |
|
|
|
| Expanding Opportunities For Inhaled Drug Delivery | Article | By Gunilla Petersson, Ph.D., Nanoform | Review the challenges and intricacies of effectively delivering drugs to the lung and the advantages of using nanoparticles and gentle particle processing techniques to enable delivery of sensitive drugs. |
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | AI may help run and optimize bioreactors at your CDMO. There is pervasive pressure to move manual (and reactive) control to AI-autonomous (predictive systems). You may already select your CDMO partially based on its systematic utilization of AI in its facilities. But at this moment of transition, while the odds are high AI may not fully reside in the manufacturing plant today, it increasingly shapes the decisions determining what and how programs get to that plant. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| How To Handle Intrinsic Product Powder Particles | Article | Dalton Pharma Services | Powder filling creates intrinsic particles that interfere with continuous monitoring. Risk‑based strategies must separate product dust from true contamination to meet Annex 1 requirements. |
|
|
|
| From Tactical Response To Strategic Imperative | White Paper | Thermo Fisher Scientific | Build flexibility into your drug development strategy to navigate change effectively, maintain momentum, and drive successful outcomes across every stage of the lifecycle. |
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
